The Food and Drug Administration issued a Complete Response Letter to Cempra Inc. (Nasdaq: CEMP) for oral and intravenous solithromycin to treat community-acquired bacterial pneumonia in adults. Shares of the pharmaceutical plummeted $3.50 to close at $2.60.
FDA issues CRL to Cempra
December 29, 2016 at 16:19 PM EST
